Form 4: Boston Scientific CEO Michael Mahoney Reports Stock Transactions
SEC Form 4 Filing
Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports acquisition and disposal of common stock and derivative securities.
Summary
- Michael Mahoney, the Chairman, President & CEO of Boston Scientific, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions involving common stock and restricted stock units.
- On February 14, 2025, 16,524 shares were acquired and 7,990 shares were disposed of at a price of $106.11.
- On February 16, 2025, 16,265 shares were acquired and 7,865 shares were disposed of at a price of $106.11.
- On February 17, 2025, 18,334 shares were acquired and 8,865 shares were disposed of at a price of $106.11.
- Mahoney also acquired 35,330 restricted stock units on February 13, 2025, and 90,915 stock options on February 13, 2025.
- Following these transactions, Mahoney directly owns 1,653,354 shares of common stock and indirectly owns 201,478 shares through a trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock transactions by the CEO, with no clear indication of positive or negative sentiment towards the company's future.
Positives
- The acquisition of restricted stock units and stock options suggests a continued alignment of Mahoney's interests with the long-term performance of Boston Scientific.
Future Outlook
The restricted stock units vest in four equal annual installments beginning on February 13, 2026.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's future prospects.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are common in the medical device industry.
- Companies like Medtronic and Abbott also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules and exercise prices are generally in line with industry norms for executive compensation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they reflect the CEO's trading activity.
- Employees may be indirectly affected by the CEO's equity holdings, as they align his interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Grant date of restricted stock units and stock options. |
| 02/14/2025 | Transaction date for common stock acquisition and disposal. |
| 02/16/2025 | Transaction date for common stock acquisition and disposal. |
| 02/17/2025 | Transaction date for common stock acquisition and disposal. |
| 02/18/2025 | Date of report filing. |
| 02/13/2026 | First vesting date for restricted stock units and stock options. |
| 02/13/2029 | Expiration date for restricted stock units. |
| 02/13/2035 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.